In the past decade, there have been major advancements in the field of cardiac imaging. New imaging techniques were developed and new tracers have become ready for routine clinical use. These new tools and techniques have and will continue to impact the current management of patients with heart failure. All of the above allowed clinicians to better understand the pathophysiology of heart failure, detect earlier alterations in cardiac structure and function, and identify prognostic markers in patients with suspected or confirmed heart failure [1] . Thus, it is no wonder that the current heart failure guidelines have multiple class I indications for the use of these new techniques across the spectrum of the diagnosis and management of heart failure patients [2, 3] .
Given these changes, Heart Failure Reviews have dedicated this issue to update the readership on the role of these imaging tests (primarily cardiovascular magnetic resonance imaging (CMR) and positron emission tomography (PET)) in the current management of heart failure patients. We put together ten articles describing how PET and CMR can serve heart failure patients.
Aljizeeri and colleagues provided a primer about the role of CMR in patients with ischemic and non-ischemic cardiomyopathy [4] . This introductory article focuses on the distinction between different types of cardiomyopathy using the myocardial late gadolinium enhancement technique (LGE).
LGE has been around for nearly two decades and remains the backbone of CMR imaging of cardiomyopathy [5] . While its presence is not specific for one cardiomyopathy, its location and pattern helps the imager determine the cardiomyopathy etiology and often guide therapy in these patients [6] [7] [8] . In addition, LGE is the main sequence used in CMR viability imaging. The utility of viability imaging have been recently questioned especially after the results of the PARR-2 trial [9] (F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease) and the Surgical Treatment for Ischemic Heart Failure (STICH) trial [10] . However, viability remains a routinely ordered test in patients with ischemic cardiomyopathy who are being considered for revascularization. Jamiel and colleagues [11] reviewed the current controversy around viability imaging in the current era and identified knowledge gaps in the viability literature. They provide recommendations that could help when applying the test results in everyday clinical care of patients.
However, many patients with cardiomyopathy do not have LGE. This is mostly seen among patients with heart failure with preserved ejection fraction. Thus, there is need for new tools to help diagnose and prognosticate these patients. These new sequences are often referred to as multiparametric mapping techniques which have rapidly evolved and made it to the clinical arena in the past few years. These include T1 mapping, T2 mapping, and T2* imaging. We discuss these imaging sequences in two papers in this issue. Radenkovic and colleagues [12] reviewed the different T1 mapping sequences that are in clinical practice. These techniques (native T1, post contrast T1, and extracellular volume estimation) have recently been adopted in numerous pathologies, as they provide non-invasive tissue characterization with the potential to replace the need for invasive biopsy. They are steadily becoming diagnostically and prognostically useful tests for different pathologies like amyloidosis and other storage disease [13, 14] , myocarditis, sarcoidosis, heart failure with preserved left ventricular ejection fraction, and even ischemic heart disease.
Lota [15] and colleagues also reviewed the role of CMR edema imaging in patients with heart failure. Edema imaging can be used in various conditions ranging from acute inflammatory and ischemic cardiomyopathy, to cardiac involvement in systemic diseases such as sarcoidosis and myocarditis. The paper also focuses on T2* imaging which is the main sequence used in the assessment of patients with suspected cardiac iron overload and cardiac hemochromatosis. Of note, this sequence can be performed in nearly 10 min without the need for contrast. Since the adoption of T2* imaging in the UK, there has been a significant decrease in the heart failure mortality of patients with cardiac iron overload [16] .
Similar advancements have been seen in cardiac PET [17] . It is a comprehensive test that allows for the assessment of myocardial perfusion, viability, and ischemia. When combined with computed tomography, it provides valuable data on plaque imaging and coronary anatomy and calcium scoring [18, 19] . The prognostic value of these tests has been well documented [20] [21] [22] [23] . However, the recent interest in PET is partly due to its ability to assess myocardial blood flow accurately and provide an assessment of vasomotor tone and coronary flow reserve (CFR). The ability to measure myocardial blood flow, both at rest and under hyperemic conditions, and CFR allows for systematic evaluation of the integrity of the entire coronary vascular bed, beyond the ordinary assessment of obstructive lesions in epicardial vessels. The value of PET derived CFR is discussed in two papers in this issue. Al Badarin and colleagues [24] reviewed the principals of the measurement of myocardial blood flow and coronary flow reserve. The paper also reviews the role of CFR in ischemic heart disease and ischemic cardiomyopathy with focus on the new prognostic value data that emerged in the past few years. In another paper, Bravo and colleagues [25] reviewed the role of CFR and myocardial blood flow in non-ischemic cardiomyopathy. This is an area of intense research activity trying to define the diagnostic and prognostic value of CFR in cardiac amyloidosis [26] , sarcoidosis, and other infiltrate diseases. Most of these patients have reduced blood flow at rest and peak hyperemia, more than what is seen in patients with ischemic heart disease. Data is starting to emerge on the diagnostic and prognostic role of CFR in this patient population.
In addition, the issue attempts a glimpse about the future of PET and CMR imaging in heart failure. There have been some tools that are not yet ready for prime time but are under investigation and development. In the past few months, there has been a new post-processing tool that allows for accurate assessment of myocardial strain using cine CMR imaging. This software can calculate the global longitudinal strain similar to what is done by echocardiography. There are a lot of on-going research activities in this area and are nicely summarized in the article by Scatteia and colleagues [27] .
In addition, multiple vendors have been manufacturing hybrid PET MRI systems. These expensive machines combine the strength of both imaging modalities but their role in cardiac imaging is not very clear. Quail and colleagues [28] provide a review of the systems (their pros and cons) and discuss what could be their potential role in cardiac pathology including ischemic heart disease and inflammatory cardiomyopathies.
Similar to the new hardware, there have been multiple new tracers that are actively tested. Saraste and colleagues [29] reviewed the role of some of the new PET tracers in the assessment of underlying pathophysiology and therapeutic options in heart failure. The review focused on multiple tracers including the long awaited 18F-Flurpiridaz and its role in assessment of ischemic heart disease. The authors also discuss sympathetic innervation imaging and its role to determine the risk of cardiac death, arrhythmia, and disease progression. Similarly, new tracers assess angiogenesis and other mechanisms involved in myocardial repair after infarction. In addition, there are many new tracers under development for the imaging of inflammatory cardiomyopathies. Qureshi and colleagues [30] also reviewed the role of CMR spectroscopy in the assessment of myocardial metabolism. While these protocols have been mostly used in research, recent developments resulted in shorter scan protocols. When combined with higher field strengths, it provides an opportunity to utilize this technology in studying and characterizing the metabolic derangements in heart failure patients.
Thus, this issue provides the reader a summary of the advances in the fields of CMR and PET and their role in the diagnosis and management of heart failure patients. Many of these tools are ready for clinical use and are widely adopted in different centers across the world. We hope that you enjoy reading this special issue and be able to apply some of these new tools in your clinical heart failure practice.
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